Want to see HK:2171 full AI Analyst Report?
CARsgen Therapeutics Holdings Ltd. (2171) Ratios
CARsgen Therapeutics Holdings Ltd. Ratios
HK:2171's free cash flow for Q2 2026 was $-132.99M. For the 2026 fiscal year, HK:2171's free cash flow was decreased by $-5.81M and operating cash flow was $-127.18M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.73 | 6.02 | 9.55 | 13.45 | 7.89 |
| Quick Ratio | 5.70 | 6.00 | 9.54 | 13.45 | 7.89 |
| Cash Ratio | 5.47 | 5.82 | 9.43 | 13.26 | 1.78 |
| Solvency Ratio | -0.13 | -1.19 | -1.49 | -2.88 | -9.22 |
| Operating Cash Flow Ratio | -1.11 | -1.61 | -2.32 | -3.76 | -1.32 |
| Short-Term Operating Cash Flow Coverage | -17.78 | -20.19 | -180.39 | -132.59 | -2.34 |
| Net Current Asset Value | $ 665.57M | $ 913.95M | $ 1.42B | $ 2.01B | $ 2.56B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.10 | 0.04 | 0.04 | 0.10 |
| Debt-to-Equity Ratio | 0.08 | 0.16 | 0.05 | 0.05 | 0.11 |
| Debt-to-Capital Ratio | 0.07 | 0.14 | 0.05 | 0.05 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.65 | 1.58 | 1.25 | 1.12 | 1.17 |
| Debt Service Coverage Ratio | -10.05 | -26.42 | -99.92 | -36.82 | -20.33 |
| Interest Coverage Ratio | -15.11 | -141.47 | -164.59 | -56.78 | -52.80 |
| Debt to Market Cap | 0.00 | 0.02 | 0.00 | 0.00 | 0.02 |
| Interest Debt Per Share | 0.12 | 0.31 | 0.16 | 0.24 | 0.63 |
| Net Debt to EBITDA | 5.36 | 1.91 | 2.46 | 2.87 | 0.08 |
| Profitability Margins | |||||
| Gross Profit Margin | 63.62% | 37.41% | 0.00% | 0.00% | 100.00% |
| EBIT Margin | -181.36% | -1906.78% | 0.00% | 0.00% | -18308.25% |
| EBITDA Margin | -157.88% | -1741.56% | 0.00% | 0.00% | -18105.07% |
| Operating Profit Margin | -82.93% | -2049.95% | 0.00% | 0.00% | -2223.32% |
| Pretax Profit Margin | -81.89% | -2023.55% | 0.00% | 0.00% | -18350.36% |
| Net Profit Margin | -77.88% | -2024.43% | 0.00% | 0.00% | -18379.98% |
| Continuous Operations Profit Margin | -81.89% | -2024.43% | 0.00% | 0.00% | -18379.98% |
| Net Income Per EBT | 95.10% | 100.04% | 100.05% | 100.15% | 100.16% |
| EBT Per EBIT | 98.75% | 98.71% | 97.36% | 101.10% | 825.36% |
| Return on Assets (ROA) | -7.57% | -47.71% | -33.13% | -32.29% | -135.34% |
| Return on Equity (ROE) | -12.49% | -75.53% | -41.50% | -36.08% | -158.32% |
| Return on Capital Employed (ROCE) | -9.59% | -56.95% | -37.25% | -34.00% | -18.42% |
| Return on Invested Capital (ROIC) | -9.36% | -55.63% | -36.98% | -33.72% | -17.13% |
| Return on Tangible Assets | -7.58% | -47.79% | -33.26% | -32.54% | -136.38% |
| Earnings Yield | -1.33% | -16.69% | -23.63% | -12.23% | -38.52% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.98 | 1.45 | 0.00 | 0.00 | 0.39 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 6.40 | 3.56 | 141.39 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.28 | 0.32 | 0.00 | 0.00 | 0.07 |
| Asset Turnover | 0.10 | 0.02 | 0.00 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.11 | 0.03 | 0.00 | 0.00 | 0.01 |
| Cash Conversion Cycle | 148.83 | 354.93 | 2.58 | 0.00 | 940.01 |
| Days of Sales Outstanding | 91.81 | 252.50 | 0.00 | 0.00 | 940.01 |
| Days of Inventory Outstanding | 57.02 | 102.44 | 2.58 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 148.83 | 354.93 | 2.58 | 0.00 | 940.01 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.41 | -0.74 | -0.82 | -1.17 | -0.93 |
| Free Cash Flow Per Share | -0.44 | -0.78 | -0.84 | -1.42 | -1.26 |
| Dividend Paid and CapEx Coverage Ratio | -37.28 | -20.93 | -47.64 | -4.64 | -2.87 |
| Capital Expenditure Coverage Ratio | -37.28 | -20.93 | -47.64 | -4.64 | -2.87 |
| Operating Cash Flow Coverage Ratio | -3.73 | -2.46 | -5.34 | -5.38 | -1.52 |
| Operating Cash Flow to Sales Ratio | -1.82 | -10.39 | 0.00 | 0.00 | -19.85 |
| Free Cash Flow Yield | -3.30% | -8.98% | -14.68% | -10.71% | -5.61% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -74.10 | -5.99 | -4.23 | -8.18 | -2.60 |
| Price-to-Sales (P/S) Ratio | 58.60 | 121.30 | 0.00 | 0.00 | 477.10 |
| Price-to-Book (P/B) Ratio | 9.40 | 4.53 | 1.76 | 2.95 | 4.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -30.30 | -11.14 | -6.81 | -9.33 | -17.83 |
| Price-to-Operating Cash Flow Ratio | -32.23 | -11.67 | -6.96 | -11.35 | -24.04 |
| Price-to-Earnings Growth (PEG) Ratio | 0.85 | -0.80 | 0.24 | 0.09 | -0.02 |
| Enterprise Value Multiple | -31.76 | -5.05 | -1.95 | -6.88 | -2.56 |
| Enterprise Value | 6.30B | 3.47B | 1.40B | 5.15B | 11.96B |
| EV to EBITDA | -31.76 | -5.05 | -1.95 | -6.88 | -2.56 |
| EV to Sales | 50.14 | 88.01 | 0.00 | 0.00 | 463.41 |
| EV to Free Cash Flow | -25.93 | -8.08 | -3.01 | -6.59 | -17.32 |
| EV to Operating Cash Flow | -27.58 | -8.47 | -3.08 | -8.01 | -23.35 |
| Tangible Book Value Per Share | 1.41 | 1.91 | 3.22 | 4.45 | 5.40 |
| Shareholders’ Equity Per Share | 1.42 | 1.91 | 3.24 | 4.48 | 5.45 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.23 | 0.07 | 0.00 | 0.00 | 0.05 |
| Net Income Per Share | -0.18 | -1.44 | -1.34 | -1.62 | -8.63 |
| Tax Burden | 0.95 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.45 | 1.06 | 0.95 | 1.11 | 1.00 |
| Research & Development to Revenue | 1.95 | 11.82 | 0.00 | 0.00 | 19.44 |
| SG&A to Revenue | 0.57 | 1.32 | 0.00 | 0.00 | 4.87 |
| Stock-Based Compensation to Revenue | 0.20 | 0.23 | 0.00 | 0.00 | 0.52 |
| Income Quality | 2.22 | 0.51 | 0.61 | 0.72 | 0.11 |
Currency in CNY